Researchers at the University of Calgary say they have developed a nanoparticle vaccine for type 1 diabetes.
The vaccine, which has tested successfully on mice, was designed to prevent the autoimmune response responsible for causing Type 1 in children without damaging immune cells protecting against disease and infection, according to an article in Diabetes.co.uk.
It not only cured mice infected with type 1 but slowed the disease’s onset in mice deemed at-risk. The mice’s general immune systems did not seem to suffer and indeed they did not contract diseases or infections at higher rates than control mice.
The vaccine has been licensed to Parvus Therapeutics commercial development, according to the blog The Future of Things. The researchers’ study has been published in the journal Immunity, but it is not available via the journal’s website.
